Fusion Pharmaceuticals Inc (Nasdaq: FUSN), a Canada-based clinical-stage oncology company, announced on Thursday that it has named Philina Lee, PhD as its new director.

Presently, Dr Lee is the senior vice president, head of portfolio strategy at Blueprint Medicines Corporation. She has 15 years of experience in the biopharmaceutical industry. She has earlier held the position of head of United States marketing for Algeta.

Fusion CEO John Valliant, PhD, said, 'Philina's depth of both precision oncology and radiopharmaceutical industry experience will be valuable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates. Additionally, her leadership and understanding relating to the commercial launch of an alpha therapy product will provide Fusion with important organisational, strategic and operational guidance during this growth period.'